National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 32712 [2017-14857]
Download as PDF
<![CDATA[
32712
Federal Register / Vol. 82, No. 135 / Monday, July 17, 2017 / Notices
asabaliauskas on DSKBBXCHB2PROD with NOTICES
government and in accordance with
federal travel regulations.
Estimated Number and Frequency of
Meetings. The Working Group will meet
not less than twice a year. The meetings
will be open to the public, except as
determined otherwise by the Secretary,
or another official to whom authority
has been delegated, in accordance with
the guidelines under Government in the
Sunshine Act, 5 U.S.C. 552b(c).
Nominations: Nominations, including
self-nominations, of individuals who
have the specified expertise and
knowledge will be considered for
appointment as public voting members
of the Working Group. A nomination
should include, at a minimum, the
following for each nominee: (1) A letter
of nomination that clearly states the
name and affiliation of the nominee, the
basis for the nomination, and a
statement from the nominee that
indicates that the individual is willing
to serve as a member of the Working
Group, if selected; (2) the nominator’s
name, address, and daytime telephone
number, and the address, telephone
number, and email address of the
individual being nominated; and (3) a
current copy of the nominee’s
curriculum vitae or resume, which
should be limited to no more than 10
pages.
Every effort will be made to ensure
that the Working Group is a diverse
group of individuals with representation
from various geographic locations, racial
and ethnic minorities, all genders, and
persons living with disabilities.
Individuals being considered for
appointment as public voting members
will be required to complete and submit
a report of their financial holdings. An
ethics review must be conducted to
ensure that individuals appointed as
public voting members of the Working
Group are not involved in any activity
that may pose a potential conflict of
interest for the official duties that are to
be performed. This is a federal ethics
requirement that must be satisfied upon
entering the position and annually
throughout the established term of
appointment on the Working Group.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Prospective Grant of Exclusive Patent
License: Development, Commercial
Application and Use of Fulvestrant in
Combination Therapy for the
Treatment of Cancers
Dated: July 12, 2017.
Donald Wright,
Acting Assistant Secretary for Health.
[FR Doc. 2017–14857 Filed 7–14–17; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Planning Grant (R34).
Date: July 31, 2017.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Jay R. Radke, Ph.D., AIDS
Review Branch, Scientific Review Program,
Division of Extramural Activities, Room
#3G11B, National Institutes of Health, NIAID,
5601 Fishers Lane MSC–9823, Bethesda, MD
20892–9823, (240) 669–5046, jay.radke@
nih.gov.
This notice is being published less than 15
days prior to the meeting due to the urgent
need to meet timing limitations imposed by
the intramural research review cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: July 10, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
[FR Doc. 2017–14965 Filed 7–14–17; 8:45 am]
BILLING CODE 4150–28–P
VerDate Sep<11>2014
17:45 Jul 14, 2017
Jkt 241001
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Commercialization
Patent License to practice the inventions
embodied in the U.S. Patents and Patent
Applications listed in the
Supplementary Information section of
this notice to NantBioScience, Inc.,
located in, California, USA.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before August 1, 2017 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Commercialization Patent
License should be directed to: Sabarni
K. Chatterjee, Ph.D., M.B.A., Senior
Licensing and Patenting Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, RM 1E530 MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702 Telephone: (240) 276–5530;
Facsimile: (240) 276–5504 Email:
sabarni.chatterjee@nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Intellectual Property
• United States Provisional Patent
Application No. 62/290,117 filed
February 02, 2016, and entitled
‘‘Fulvestrant Improves Immunemediated Cytotoxic Lysis of Cancer
Cells.’’ [HHS Reference No. E–066–
2016/0–US–01];
• International PCT Application No.
PCT/US2017/015829 filed January 31,
2017, entitled ‘‘Fulvestrant Improves
Immune-mediated Cytotoxic Lysis of
Cancer Cells.’’ [HHS Reference No. E–
066–2016/0–PCT–02]; and U.S. and
foreign patent applications claiming
priority to the aforementioned
applications.
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
E:\FR\FM\17JYN1.SGM
17JYN1
]]>Agencies
[Federal Register Volume 82, Number 135 (Monday, July 17, 2017)]
[Notices]
[Page 32712]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-14857]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Clinical Trial Planning Grant
(R34).
Date: July 31, 2017.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Jay R. Radke, Ph.D., AIDS Review Branch,
Scientific Review Program, Division of Extramural Activities, Room
#3G11B, National Institutes of Health, NIAID, 5601 Fishers Lane MSC-
9823, Bethesda, MD 20892-9823, (240) 669-5046, jay.radke@nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the urgent need to meet timing limitations imposed by
the intramural research review cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: July 10, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-14857 Filed 7-14-17; 8:45 am]
BILLING CODE 4140-01-P
